Equities

China Medical System Holdings Ltd

China Medical System Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)9.10
  • Today's Change0.08 / 0.89%
  • Shares traded15.30m
  • 1 Year change-23.91%
  • Beta1.0787
Data delayed at least 15 minutes, as of Oct 10 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

China Medical System Holdings Ltd is an investment holding company principally engaged in the production of medicines, as well as marketing, promotion and sales of drugs. The Company's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The Company distributes its products within domestic market and to overseas markets.

  • Revenue in HKD (TTM)7.70bn
  • Net income in HKD1.53bn
  • Incorporated2006
  • Employees5.78k
  • Location
    China Medical System Holdings LtdUnit 2106, 21/F, Island Place Tower, 510, North Point Hong KongHKG
  • Phone+86 75 582416868
  • Fax+86 75 582416622
  • Websitehttps://web.cms.net.cn/zh/home/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Luye Pharma Group Ltd6.93bn845.64m12.30bn5.23k14.550.86087.231.780.22480.22481.843.800.2362.443.021,314,909.003.112.805.474.4568.7370.5313.1810.391.203.140.410311.822.703.50-11.94-16.39-14.05--
Shanghai Henlius Biotech Inc6.19bn759.89m12.36bn3.55k16.314.3710.612.001.391.3911.345.210.57641.906.821,702,200.007.07-8.5914.25-14.1473.2371.7712.27-27.370.3297.600.6113--67.82273.51178.53--49.14--
SSY Group Ltd6.47bn1.37bn12.42bn5.80k9.141.726.791.920.45930.45932.182.440.54182.753.071,155,141.0011.5410.5114.8814.0354.3958.7221.3018.622.0628.650.32338.560.45059.1017.447.663.9413.56
3SBio Inc9.24bn1.82bn16.31bn5.61k9.111.037.221.760.74730.74733.796.590.35751.526.871,708,233.007.257.4410.269.2985.9482.9120.2721.501.57141.550.1998--13.8411.26-19.133.948.78--
Simcere Pharmaceutical Group Ltd6.96bn-1.21bn16.68bn6.41k--2.21--2.40-0.4626-0.46262.702.980.51982.192.64990,578.20-9.0410.17-11.7115.6077.0278.82-17.4017.501.880.47210.146146.684.497.92-23.22-0.521323.93--
Grand Pharmaceutical Group Ltd10.59bn2.41bn17.82bn10.78k7.291.136.201.680.68850.68853.034.430.44723.624.541,005,064.0010.2510.0914.2114.0159.0061.9722.9222.351.09--0.223226.9410.1212.06-9.5921.415.6924.77
Zai Lab Ltd2.51bn-2.32bn18.99bn2.18k--3.42--7.57-2.39-2.392.585.580.30833.045.52---28.50-37.72-34.92-42.7263.1764.75-92.44-282.443.29--0.0908--24.03360.0324.51---3.45--
The United Laboratories Intl. Hldgs Ltd.15.38bn3.19bn19.91bn15.00k6.241.345.221.301.761.768.468.170.65783.305.671,025,069.0013.657.8920.7212.6446.1544.1720.7512.731.72--0.153228.9921.2212.8470.8531.6624.1946.04
China Traditional Chinese Med Hldg CoLtd18.88bn1.01bn22.11bn17.72k21.950.94259.631.170.200.203.754.660.4531.541.821,091,315.002.624.604.017.0749.8657.075.779.771.517.390.180817.3526.699.9968.11-2.24-12.75--
China Medical System Holdings Ltd7.70bn1.53bn22.20bn5.78k14.571.2612.552.880.62460.62463.157.230.3842.895.651,350,396.007.5118.448.5321.1474.1375.4719.5634.263.97--0.066740.14-12.438.08-26.335.3538.695.19
HUTCHMED (China) Ltd4.75bn-326.14m27.32bn1.97k--4.75--5.76-0.3881-0.38815.506.600.47757.104.152,387,551.00-3.30-14.35-4.65-20.4341.6736.57-6.91-31.442.68--0.0984--96.5231.38127.93--38.65--
WuXi XDC Cayman Inc3.07bn652.56m28.49bn1.50k44.304.3338.339.280.53610.53612.715.490.558621.312.852,604,699.0011.88--15.43--30.96--21.27--4.02--0.0113--114.44--82.07------
Data as of Oct 10 2024. Currency figures normalised to China Medical System Holdings Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

8.73%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Jul 202447.17m1.93%
Lazard Asset Management LLCas of 30 Jun 202430.24m1.24%
Dimensional Fund Advisors LPas of 04 Jul 202430.11m1.23%
Bosera Asset Management Co., Ltd.as of 31 Dec 202321.63m0.89%
Fidelity Management & Research Co. LLCas of 30 Jun 202418.78m0.77%
GF Fund Management Co., Ltd.as of 31 Dec 202317.38m0.71%
BlackRock Fund Advisorsas of 04 Jul 202415.46m0.63%
Norges Bank Investment Managementas of 31 Dec 202314.74m0.60%
Bankinter Gesti�n de Activos SA SGIICas of 31 Dec 20239.23m0.38%
Handelsbanken Fonder ABas of 31 Jul 20248.11m0.33%
More ▼
Data from 31 Dec 2023 - 06 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.